Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15908278 | 0.81 | KMT2A (0.43) | TDP1MEN1KMT2ANPC1USP2 | |
| SCHEMBL13453317 | 0.72 | ALDH1A1 (0.50) | SLC6A2SLC6A4SLC6A3ALDH1A1MAPT | |
| SCHEMBL12156616 | 0.72 | ALDH1A1 (0.50) | SLC6A2SLC6A4SLC6A3ALDH1A1MAPT | |
| SCHEMBL23032028 | 0.72 | HCRTR1 (0.30) | — | |
| SCHEMBL13059128 | 0.72 | SLC6A2 (0.35) | SLC6A2SLC6A4SLC6A3ALDH1A1MAPT | |
| SCHEMBL12264368 | 0.71 | ALDH1A1 (0.36) | SLC6A2SLC6A4SLC6A3ALDH1A1MAPT | |
| SCHEMBL22413569 | 0.71 | DRD2 (0.42) | ALDH1A1MAPTTDP1NPC1 | |
| SCHEMBL8367487 | 0.69 | ALDH1A1 (0.33) | ALDH1A1MAPTHPGDALOX12TDP1 | |
| SCHEMBL9826854 | 0.69 | HTR2A (0.42) | SLC6A2SLC6A4SLC6A3ALDH1A1MAPT | |
| SCHEMBL13047369 | 0.69 | HTR2A (0.42) | SLC6A2SLC6A4SLC6A3ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183280-B2 | FAP inhibitors | VANTIA LIMITED (GB) | 2012-05-22 | — | — | US | disclosed |
| US-20100081701-A1 | FAP inhibitors | VANTIA LIMITED (GB) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081701-A1 | FAP inhibitors | FAP, APC, SERPINB1 | SLC6A2 4784/4885SLC6A4 4730/4885SLC6A3 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.